Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | CD274 | Q9NZQ7 | 9/20 | 0.35 |
| ▸ | PDCD1 | Q15116 | 7/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | KCNA5 | P22460 | 3/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.33 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22675491 | 0.91 | MEN1 (0.37) | GPR119CD274PDCD1MAPK1KCNA5 | |
| SCHEMBL22675492 | 0.90 | IRAK4 (0.39) | KCNA5IRAK4IRAK1 | |
| SCHEMBL22675479 | 0.80 | CD274 (0.48) | CD274PDCD1 | |
| SCHEMBL29984262 | 0.78 | CD274 (0.46) | CD274PDCD1PDCD1LG2 | |
| SCHEMBL31108217 | 0.77 | CD274 (0.46) | CD274PDCD1PDCD1LG2 | |
| SCHEMBL22675478 | 0.75 | CD274 (0.56) | PARP1CD274PDCD1PDCD1LG2 | |
| SCHEMBL23200203 | 0.74 | AAK1 (0.38) | KCNA5 | |
| SCHEMBL38664462 | 0.74 | DDB1 (0.34) | KCNA5IRAK4IRAK1 | |
| SCHEMBL25664268 | 0.74 | DDB1 (0.34) | KCNA5IRAK4IRAK1 | |
| SCHEMBL23198920 | 0.73 | PDCD1 (0.47) | CD274PDCD1IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210386721-A1 | SUBSTITUTED PHENYLPROPENYL PYRIDINE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL APPLICATIONS | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2021-12-16 | — | — | US | disclosed |
| WO-2020228649-A1 | SUBSTITUTED PHENYLPROPENYLPYRIDINE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 上海海雁医药科技有限公司 | 2020-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210386721-A1 | SUBSTITUTED PHENYLPROPENYL PYRIDINE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL APPLICATIONS | PDCD1, CD274, PDCD1LG2 | PARP1 172/4885GPR119 3211/4885CD274 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.